<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548005" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548005/" /><meta name="ncbi_pagename" content="Propafenone - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Propafenone - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Propafenone" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2014/01/23" /><meta name="citation_pmid" content="31643337" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548005/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Propafenone" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2014/01/23" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548005/" /><meta name="description" content="Propafenone is an oral antiarrhythmic agent that has been in wide use for several decades. Long term propafenone therapy is associated with a low rate of serum aminotransferase elevations and therapy rarely can cause a self limited, acute cholestatic liver injury." /><meta name="og:title" content="Propafenone" /><meta name="og:type" content="book" /><meta name="og:description" content="Propafenone is an oral antiarrhythmic agent that has been in wide use for several decades. Long term propafenone therapy is associated with a low rate of serum aminotransferase elevations and therapy rarely can cause a self limited, acute cholestatic liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548005/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Propafenone/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548005/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C7505046639810000000009CD0302.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548005_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548005_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Promethazine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Propantheline/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548005_"><span class="title" itemprop="name">Propafenone</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 23, 2014</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Propafenone.OVERVIEW"><h2 id="_Propafenone_OVERVIEW_">OVERVIEW</h2><div id="Propafenone.Introduction"><h3>Introduction</h3><p>Propafenone is an oral antiarrhythmic agent that has been in wide use for several decades. Long term propafenone therapy is associated with a low rate of serum aminotransferase elevations and therapy rarely can cause a self limited, acute cholestatic liver injury.</p></div><div id="Propafenone.Background"><h3>Background</h3><p>Propafenone (proe" pa fee' none) is an analogue of the local anesthetic procaine and has electrophysiological effects that resemble quinidine (antiarrhythmic Class IC). Propafenone appears to act by blocking open sodium channels and outward potassium channels. As a consequence, it decreases cardiac automaticity, increases refractory periods and slows conduction. Propafenone was approved for use in the United States in 1989, and current approved indications include prevention of recurrence of symptomatic atrial fibrillation after cardioversion in patients without structural heart disease, and for suppression of life threatening ventricular arrhythmias. Propafenone is available as tablets of 150, 225 and 300 mg and as extended release capsules of 225, 325 and 425 mg generically under the brand name Rythmol. The usual maintenance dose in adults of standard release forms is 150 to 300 mg every 8 hours and 225 to 425 mg of the sustained release forms every 12 hours. The most common side effects include dizziness, fatigue, headache, anxiety, gastrointestinal upset, change in taste and blurred vision.</p></div><div id="Propafenone.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In clinical trials, propafenone was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Several instances of clinically apparent liver injury have been reported in patients receiving propafenone. Patients usually present with symptoms of jaundice and pruritus 2 to 8 weeks after starting propafenone, and the pattern of serum enzyme elevations are typically mixed (Case 1) or cholestatic (Case 2). Immunoallergic and autoimmune features are uncommon. While the jaundice can be prolonged, patients typically recover in 1 to 3 months.</p></div><div id="Propafenone.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which propafenone causes liver injury is unknown. Propafenone is extensively metabolized in the liver by the cytochrome P450 system (predominantly CYP 2D6).</p></div><div id="Propafenone.Outcome_and_Management"><h3>Outcome and Management</h3><p>The severity of hepatic injury due to propafenone ranges from mild and transient serum enzyme elevations to acute cholestatic hepatitis. Propafenone has not been linked to acute liver failure, chronic liver injury or vanishing bile duct syndrome. Recurrence upon reexposure is common and should be avoided. There is no evidence for cross sensitivity to the hepatic injury of propafenone with other antiarrhythmic agents.</p><p>Drug Class: <a href="/books/n/livertox/AntiarrhythmicAgents/">Antiarrhythmic Agents</a></p></div></div><div id="Propafenone.CASE_REPORTS"><h2 id="_Propafenone_CASE_REPORTS_">CASE REPORTS</h2><div id="Propafenone.Case_1._Cholestatic_hepatiti"><h3>Case 1. Cholestatic hepatitis due to propafenone.</h3><p>[Modified from: Arinzon Z, Fridman R. [Liver function test impairment induced by propafenone in a 73 year old woman]. Harefuah 2001; 140: 1010-3, 1119. Hebrew. <a href="https://www.ncbi.nlm.nih.gov/pubmed/11759372" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 73 year old woman developed itching two weeks after starting propafenone (450 mg daily) for atrial fibrillation. She denied jaundice, abdominal pain, rash and fever. She had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. She had known atherosclerosis, coronary artery disease, cerebrovascular disease, transient ischemic attacks, chronic obstructive pulmonary disease, diabetes and dyslipidemia. Her medications taken chronically included aspirin (100 mg daily), isosorbide mononitrate (20 mg twice daily), NPH insulin (8 units daily), glibenclamide (5 mg three times daily) and metformin (850 mg daily). Laboratory testing showed elevations in serum enzymes, but normal bilirubin (Table). Tests for hepatitis A, B and C were negative and ultrasound of the liver showed no evidence for biliary obstruction. Once propafenone was stopped and replaced by verapamil (120 mg daily), serum enzymes fell into the normal range. When she redeveloped atrial fibrillation 6 months later, propafenone was restarted, but her serum enzymes rapidly became abnormal, and it was again stopped. Five weeks later she redeveloped itching and was again found to have elevations in serum enzymes. On questioning, she reported restarting propafenone on her own.</p><div id="Propafenone.Key_Points1"><h4>Key Points</h4><div id="Propafenone.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548005/table/Propafenone.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Propafenone.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Propafenone (450 mg daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Mixed (R=2.1)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1+ (enzyme elevations without jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Aspirin, glibenclamide, metformin, isosorbide mononitrate, insulin</td></tr></tbody></table></div></div></div><div id="Propafenone.Laboratory_Values1"><h4>Laboratory Values</h4><div id="Propafenone.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548005/table/Propafenone.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Propafenone.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">10</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">58</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">15</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">53</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">125</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">148</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.itching/">Itching</a></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">100</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">268</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.6</td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Propafenone stopped</td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">34</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">148</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">9 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 days</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">14</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">72</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1 hd_h_Propafenone.T2_1_1_1_2 hd_h_Propafenone.T2_1_1_1_3 hd_h_Propafenone.T2_1_1_1_4 hd_h_Propafenone.T2_1_1_1_5 hd_h_Propafenone.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Propafenone restarted due to recurrence of atrial fibrillation</td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">18</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">65</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">145</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">240</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Propafenone stopped</td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">24</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">125</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">14</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">45</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1 hd_h_Propafenone.T2_1_1_1_2 hd_h_Propafenone.T2_1_1_1_3 hd_h_Propafenone.T2_1_1_1_4 hd_h_Propafenone.T2_1_1_1_5 hd_h_Propafenone.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Propafenone restarted by the patient</td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">1 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">150</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">275</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.itching/">Itching</a>, drug stopped</td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">16</td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">70</td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T2_1_1_1_1 hd_h_Propafenone.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Propafenone.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;42</b></td><td headers="hd_h_Propafenone.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Propafenone.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Propafenone.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Propafenone.Comment1"><h4>Comment</h4><p>This patient developed a mixed pattern of serum enzyme elevations without jaundice on three occasions while taking propafenone. On each occasion, she was symptomatic with itching, suggesting a cholestatic liver injury. At least a dozen cases of cholestatic hepatitis have been reported associated with propafenone use. The latency to onset has ranged from 1 to 6 weeks and the pattern of enzyme elevation is usually cholestatic or mixed. Most patients have had mild jaundice and all cases have recovered with stopping the medication. As this case demonstrates, recurrence on reexposure is typical, the recurrences having a similar latency and severity. This phenomenon is different from cases of drug induced immunoallergic hepatitis that usually recur within days of reexposure with a more severe and abrupt onset and course.</p><p>[Translation courtesy of Dr. Yaron Rotman.]</p></div></div><div id="Propafenone.Case_2._Cholestatic_hepatiti"><h3>Case 2. Cholestatic hepatitis due to propafenone.</h3><p>[Modified from: La Brocca A. [Hepatic toxicity of propafenone: a case description]. Ann Ital Med Int 2002; 17: 261-4. Italian. <a href="https://www.ncbi.nlm.nih.gov/pubmed/12532566" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 62 year old woman was found to have abnormal liver tests one month after starting propafenone (450 mg daily) for atrial fibrillation. At that point, she had no symptoms of liver disease and specifically denied abdominal pain, dark urine, rash and fever. She had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. She had a history of breast cancer treated with mastectomy 30 years previously. She also had adult-onset diabetes for which she took insulin. The liver test abnormalities were thought to be due to malignancy and, because the arrhythmias were not adequately controlled, propafenone was continued and the dose was increased to 600 mg daily. Over the next few weeks she developed nausea and liver tests worsened (Table). Tests for hepatitis A, B and C were negative as were autoantibodies. Ultrasound and computerized tomography of the abdomen showed no evidence of biliary obstruction, gall stones or malignancy. Propafenone was discontinued and she was treated with sotalol (150 mg daily). Over the next two months, liver tests returned to normal.</p><div id="Propafenone.Key_Points2"><h4>Key Points</h4><div id="Propafenone.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548005/table/Propafenone.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Propafenone.T3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Propafenone (450 to 600 mg daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Cholestatic (R=1.2)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1+ (enzyme elevations and symptoms without jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Insulin</td></tr></tbody></table></div></div></div><div id="Propafenone.Laboratory_Values2"><h4>Laboratory Values</h4><div id="Propafenone.T4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548005/table/Propafenone.T4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Propafenone.T4_lrgtbl__"><table><thead><tr><th id="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">18</td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">182</td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.6</td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Atrial fibrillation</td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">12</td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">185</td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.7</td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Propafenone started</td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">202</td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">1489</td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Dose increase</td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">160</td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">2156</td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.3</td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Nausea</td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1 hd_h_Propafenone.T4_1_1_1_2 hd_h_Propafenone.T4_1_1_1_3 hd_h_Propafenone.T4_1_1_1_4 hd_h_Propafenone.T4_1_1_1_5 hd_h_Propafenone.T4_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Propafenone stopped</td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">41</td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">992</td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12 weeks</td><td headers="hd_h_Propafenone.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">235</td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Propafenone.T4_1_1_1_1 hd_h_Propafenone.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Propafenone.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;31</b></td><td headers="hd_h_Propafenone.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;240</b></td><td headers="hd_h_Propafenone.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Propafenone.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Propafenone.Comment2"><h4>Comment</h4><p>This patient developed a mild cholestatic hepatitis within a month of starting propafenone. The abnormal liver tests were initially attributed to possible malignancy, but after lack of evidence of cancer on imaging, propafenone was considered the likely cause and it was discontinued, whereupon symptoms rapidly improved and liver tests returned to normal within the next two months. Typical of propafenone is the latency to onset of 3-6 weeks, mild cholestatic hepatitis and prompt improvement on stopping.</p></div></div></div><div id="Propafenone.PRODUCT_INFORMATION"><h2 id="_Propafenone_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Propafenone.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Propafenone &#x02013; Generic, Rythmol&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiarrhythmic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Propafenone" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Propafenone.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Propafenone_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Propafenone.T5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548005/table/Propafenone.T5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Propafenone.T5_lrgtbl__"><table><thead><tr><th id="hd_h_Propafenone.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Propafenone.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Propafenone.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Propafenone.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Propafenone.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Propafenone</td><td headers="hd_h_Propafenone.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135004191" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">54063-53-5</a></td><td headers="hd_h_Propafenone.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C21-H27-N-O3</td><td headers="hd_h_Propafenone.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548005/bin/Propafenone_Structure.jpg" alt="Chemical Structure for Propafenone" /></div></td></tr></tbody></table></div></div></div><div id="Propafenone.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Propafenone_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 23 January 2014</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Propafenone.R1">Zimmerman HJ. Antiarrhythmics. Drugs used in cardiovascular disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 642-4.<div><i>(Expert review of hepatotoxicity of antiarrhythmics published in 1999; mentions that propafenone is a rare cause of cholestatic jaundice).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R2">De Marzio DH, Navarro VJ. Hepatotoxicity of cardiovascular and antidiabetic drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 524.<div><i>(Review of hepatotoxicity of cardiovascular agents mentions that propafenone can cause a mixed pattern of injury usually after 2-6 weeks of therapy).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R3">Sampson KJ, Kass RS. Antiarrhythmic drugs. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 815-60.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R4">Schuff-Werner P, Kaiser D. [Cholestatic hepatitis following antiarrhythmic propafenone therapy]. Dtsch Med Wochenschr 1980; 105: 137-8.  [<a href="/pubmed/7351197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7351197</span></a>]<div><i>(Two cases; 35 year old woman developed malaise 4 weeks after starting propafenone [bilirubin 1.1 mg/dL, ALT 289 U/L, Alk P 826 U/L], resolving within 4 weeks of stopping; 60 year old woman developed malaise within days of starting propafenone [ALT 115 U/L, Alk P slightly elevated], resolving within 2 weeks).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R5">Schuff-Werner P, Kaiser D, L&#x000fc;ders CJ, Berg PA. [Propafenon-induced cholestatic liver injury&#x02014;a further example for allergic drug hepatitis (author's transl)]. Z Gastroenterol 1981; 19: 673-9. German.  [<a href="/pubmed/6117993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6117993</span></a>]<div><i>(Further analysis of previously reported cases, one had positive lymphocyte stimulation to propafenone).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R6">Konz KH, Berg PA, Seipel L. [Cholestasis after antiarrhythmic therapy with propafenone]. Dtsch Med Wochenschr 1984; 109: 1525-7. German.  [<a href="/pubmed/6206993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6206993</span></a>]<div><i>(84 year old man developed nausea 6 days after starting propafenone followed by jaundice and pruritus [bilirubin 10.8 mg/dL, ALT 57 U/L, Alk P 515 U/L], with recovery in two months; patient then gave history of jaundice during previous course of propafenone arising after 33 days with cholestatic course).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R7">Libersa C, Caron J, Pladys A, Beuscart R, Kacet S, Wajman A, Connell C, et al. Propafenone versus disopyramide: a double-blind randomized crossover trial in patients presenting chronic ventricular arrhythmias. Clin Cardiol 1987; 10: 405-10.  [<a href="/pubmed/2440632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2440632</span></a>]<div><i>(Ten patients with ventricular arrhythmias were treated with disopyramide vs propafenone vs placebo in a crossover study for 6 days each; no change in chemical parameters).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R8">Jonason T, Ringqvist I, Bandh S, Nilsson G, Nilsson H, Lidell C, Bjerle P, et al. Propafenone versus disopyramide for treatment of chronic symptomatic ventricular arrhythmias. A multicenter study. Acta Med Scand 1988; 223: 515-23.  [<a href="/pubmed/3291557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3291557</span></a>]<div><i>(38 patients with symptomatic ventricular arrhythmias were treated with either propafenone or disopyramide for 28 days; propafenone had fewer side effects; no mention of liver injury or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R9">Funck-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. N Engl J Med 1990; 322: 518-25.  [<a href="/pubmed/2405273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2405273</span></a>]<div><i>(Review of propafenone; approved for severe ventricular arrhythmias; common side effects are dizziness, taste disturbances, blurred vision and nausea. Rare cases of cholestatic hepatitis have been reported).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R10">Propafenone for cardiac arrhythmias. Med Lett Drugs Ther 1990; 32: 37-8.  [<a href="/pubmed/2182990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2182990</span></a>]<div><i>(Short summary of efficacy and safety of propafenone published soon after its approval in the US; adverse effects include dizziness, change in taste, blurred vision, abdominal discomfort, anorexia, and nausea; can worsen heart failure; no mention of hepatic adverse effects).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R11">Spinler SA, Elder CA, Kindwall KE. Propafenone-induced liver injury. Ann Pharmacother 1992; 26: 926-8.  [<a href="/pubmed/1354511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1354511</span></a>]<div><i>(71 year old woman developed serum enzyme elevations without symptoms 1 month after starting propafenone [bilirubin 1.1 mg/dL, ALT 80 U/L, Alk P 512 U/L], not resolving on lowering dose, but resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R12">Mondardini A, Pasquino P, Bernardi P, Aluffi E, Tartaglino B, Mazzucco G, Bonino F, et al. Propafenone-induced liver injury: report of a case and review of the literature. Gastroenterology 1993; 104: 1524-6.  [<a href="/pubmed/8482464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8482464</span></a>]<div><i>(66 year old man took propafenone for 2 weeks, presenting ten days later with jaundice and pruritus [bilirubin 6.2 mg/dL, ALT 127 U/L, Alk P 553 U/L], resolving on stopping and reappearing within 2 weeks of restarting).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R13">Elizalde JI, Batallier R, Bruix J, Rodes J. [Hepatotixicity of propafenone]. Gastroenterol Hepatol 1994; 17: 382-3. Not in PubMed.<div><i>(62 year old man developed fatigue at 3 and jaundice at 6 weeks after starting propafenone [bilirubin 6.8 mg/dL, ALT 501 U/L, Alk P 1512 U/L], resolving 2 months after stopping).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R14">Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther 1996; 10: 145-52.  [<a href="/pubmed/8842506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8842506</span></a>]<div><i>(Controlled trial of propafenone vs disopyramide in 56 patients after cardioversion of atrial fibrillation; similar efficacy, but side effects were more frequent with disopyramide; no mention of hepatic side effects or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R15">Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/ flutter. The Flecainide AF French Study Group. Am J Cardiol 1996; 77: 66A-71A.  [<a href="/pubmed/8607394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8607394</span></a>]<div><i>(In a controlled trial in 96 patients with episodic atrial fibrillation, oral flecainide and propafenone were equally effective, but side effects were common, largely dizziness, headache and gastrointestinal disturbances; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R16">Chimienti M, Cullen MT Jr, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 1996; 77: 60A-75A.  [<a href="/pubmed/8607393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8607393</span></a>]<div><i>(In a controlled trial in 200 patients with episodic atrial fibrillation, oral flecainide and propafenone had similar efficacy and tolerance; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R17">Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000; 84: 339-46.  [<a href="/pmc/articles/PMC1760959/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1760959</span></a>] [<a href="/pubmed/10956304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10956304</span></a>]<div><i>(Overview of antiarrhythmic drugs which are separated in four classes based upon molecular target: I being sodium channel blockers; II beta blockers; III potassium channel blockers; and, IV calcium channel blockers; some agents having multiple targets).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R18">Arinzon Z, Fridman R. [Liver function test impairment induced by propafenone in a 73 year old woman]. Harefuah 2001; 140: 1010-3, 1119. Hebrew.  [<a href="/pubmed/11759372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11759372</span></a>]<div><i>(73 year old woman developed itching 2 weeks after starting propafenone [bilirubin 0.5 mg/dL, ALT 125 U/L, Alk P 148 U/L], values becoming normal after it was stopped and both symptoms and liver enzyme abnormalities returning on restarting two more times [bilirubin always normal and peak Alk P 268 U/L: Case 1).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R19">Gandolfi A, Rota E, Zanghieri G, Tolomelli S, Bagnulo A, Mengoli M. [Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature]. Recenti Prog Med 2001; 92: 197-9. Italian.  [<a href="/pubmed/11320851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11320851</span></a>]<div><i>(Case of self limited acute cholestatic hepatitis arising 3 weeks after starting propafenone: abstract only).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R20">La Brocca A. [Hepatic toxicity of propafenone: a case description]. Ann Ital Med Int 2002; 17: 261-4. Italian.  [<a href="/pubmed/12532566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12532566</span></a>]<div><i>(62 year old woman developed nausea and abnormal liver tests two months after starting propafenone for atrial fibrillation [bilirubin 1.4 mg/dL, ALT 202 U/L, Alk P 1489 U/L], resolving within two months of stopping: Case 2).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R21">Grieco A, Forgione A, Giorgi A, Miele L, Gasbarrini G. Propafenone-related cholestatic hepatitis in an elderly patient. Ital Heart J 2002; 3: 431-4.  [<a href="/pubmed/12189974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12189974</span></a>]<div><i>(84 year old man developed pruritus and jaundice 3 weeks after starting propafenone [bilirubin 10.7 mg/dL, ALT 116 U/L, Alk P 1655 U/L], resolving over next 8 weeks).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R22">McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139: 1018-33.  [<a href="/pubmed/14678922" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14678922</span></a>]<div><i>(Systematic review of literature on efficacy and safety of drugs for atrial fibrillation; propafenone has been shown to be effective in conversion of atrial fibrillation to normal sinus rhythm and its subsequent maintenance; hepatic side effects are not discussed).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R23">Cocozzella D, Curciarello J, Corallini O, Olivera A, Alburquerque MM, Fraquelli E, Zamagna L, et al. Propafenone hepatotoxicity: report of two new cases. Dig Dis Sci 2003; 48: 354-7.  [<a href="/pubmed/12643615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12643615</span></a>]<div><i>(2 cases; 67 year old woman developed jaundice and pruritus 6 weeks after starting propafenone [bilirubin 3.6 mg/dL, ALT 22 U/L, Alk P 770 U/L], resolving in 2 weeks; 69 year old woman developed jaundice and pruritus 7 months after starting propafenone [bilirubin 7.4 mg/dL, ALT 100 U/L, Alk P 1020 U/L], resolving in several months).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R24">Marrt&#x000ed;n EP, Cervantes JL, Yang&#x000fc;ela J. [Propafenone hepatotoxicity]. Rev Esp Enferm Dig 2004; 96: 734-5. Spanish.  [<a href="/pubmed/15537382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15537382</span></a>]<div><i>(76 year old woman developed fatigue 1 month after starting propafenone [bilirubin 1.6 mg/dL, ALT 208 U/L, Alk P 1257 U/L], resolving almost completely within 3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R25">Drugs for cardiac arrhythmias. Treat Guidel Med Lett 2007; 5: 51-8.  [<a href="/pubmed/17505408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17505408</span></a>]<div><i>(Concise review of drugs for arrhythmias; propafenone is effective in preventing paroxysmal supraventricular tachycardia and atrial fibrillation in &#x0201c;otherwise healthy hearts&#x0201d;; mentions hepatotoxicity as an adverse event).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R26">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, 2 cases were attributed to amiodarone and 1 to profafenone, but none to other antiarrhythmic agents).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R27">Treatment of atrial fibrillation. Treat Guidel Med Lett 2010; 8 (97): 65-70;  [<a href="/pubmed/20733547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20733547</span></a>]<div><i>(Concise review of efficacy and safety of drugs for atrial fibrillation; propafenone is effective in maintaining sinus rhythm after cardioversion and is generally reserved for patients with structurally normal hearts; side effects can include bradycardia, dizziness, blurred vision, nervousness and headache; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Propafenone.R28">Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits. Int J Cardiol 2012; 155: 362-71.  [<a href="/pubmed/21708411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21708411</span></a>]<div><i>(Review of the safety and efficacy of antiarrhythmic drugs used to maintain normal sinus rhythm; no discussion of hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548005</span><span class="label">PMID: <a href="/pubmed/31643337" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643337</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Promethazine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Propantheline/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548005&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548005/?report=reader">PubReader</a></li><li><a href="/books/NBK548005/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548005" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548005" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Propafenone. [Updated 2014 Jan 23].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548005/pdf/Bookshelf_NBK548005.pdf">PDF version of this page</a> (129K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Propafenone/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Propafenone: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Propafenone" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Propafenone: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4861436" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4861436" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4861436" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/1354511" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Propafenone-induced liver injury.</a><span class="source">[Ann Pharmacother. 1992]</span><div class="brieflinkpop offscreen_noflow">Propafenone-induced liver injury.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Spinler SA, Elder CA, Kindwall KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Pharmacother. 1992 Jul-Aug; 26(7-8):926-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12532566" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Hepatic toxicity of propafenone: a case description].</a><span class="source">[Ann Ital Med Int. 2002]</span><div class="brieflinkpop offscreen_noflow">[Hepatic toxicity of propafenone: a case description].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">La Brocca A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Ital Med Int. 2002 Oct-Dec; 17(4):261-4. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8482464" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propafenone-induced liver injury: report of a case and review of the literature.</a><span class="source">[Gastroenterology. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propafenone-induced liver injury: report of a case and review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mondardini A, Pasquino P, Bernardi P, Aluffi E, Tartaglino B, Mazzucco G, Bonino F, Verme G, Negro F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterology. 1993 May; 104(5):1524-6. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/3322781" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.</a><span class="source">[Drugs. 1987]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Harron DW, Brogden RN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 1987 Dec; 34(6):617-47. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11320851" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature].</a><span class="source">[Recenti Prog Med. 2001]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gandolfi A, Rota E, Zanghieri G, Tolomelli S, Bagnulo A, Mengoli M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Recenti Prog Med. 2001 Mar; 92(3):197-9. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643337" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643337" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604690259e31203af6b96621">Propafenone - LiverTox</a><div class="ralinkpop offscreen_noflow">Propafenone - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:59:18-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal105&amp;ncbi_phid=CE8C7505046639810000000009CD0302&amp;ncbi_session=CE8C750504690251_2509SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548005%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548005&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548005/&amp;ncbi_pagename=Propafenone - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C750504690251_2509SID /projects/books/PBooks@9.2 portal105 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>